Drug Trial Radar · NCT01682083
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
870
Actual
Start
Jan 8, 2013
Primary completion
Jun 30, 2017
Study completion Jul 31, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk (Stage IIIa \[lymph node metastasis \>1 mm\], IIIb or IIIc) cutaneous melanoma were screened for eligibility. Approximately 852 patients were planned to be randomized in a 1:1 ratio, stratified by BRAF mutation status (V600E, V600K) and stage of disease (Stage IIIa, IIIb, IIIc). Patients received either dabrafenib (150 milligram (mg) twice daily \[BID\]) and trametinib (2 mg once daily \[QD\]) combination therapy or 2 matching placebos (one each for dabrafenib and trametinib) for 12 months or until disease recurrence, death, unacceptable toxicity, or withdrawal of consent. Patients were followed for disease recurrence and survival during and after the treatment period. The study did not permit crossover. Doses of study treatment could be modified and/or interrupted for management of toxicities associated with study treatment.
Conditions
- Melanoma
Interventions
DabrafenibDrug
Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
TrametinibDrug
Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
PlacebosDrug
The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Relapse-free Survival (RFS) EventsTime frame: Approximately 4 years
- Relapse-free Survival (RFS)Time frame: Approximately 4 years
Locations
168 sites in 25 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Lake Worth, Florida
Novartis Investigative Site
Orlando, Florida
Novartis Investigative Site
Tampa, Florida
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Atlanta, Georgia
Novartis Investigative Site
Lutherville-Timonium, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Ann Arbor, Michigan
Novartis Investigative Site
Winston-Salem, North Carolina
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
Nashville, Tennessee
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina
Novartis Investigative Site
Gateshead, New South Wales, Australia
Novartis Investigative Site
North Sydney, New South Wales, Australia
Novartis Investigative Site
Tweed Heads, New South Wales, Australia
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Greenslopes, Queensland, Australia
Novartis Investigative Site
Woolloongabba, Queensland, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
Heidelberg, Victoria, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Wels, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Leuven, Belgium
Showing 40 of 168 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.